The Community Resource in Targeted Therapies
Driving Knowledge. Empowering Change. Optimizing Outcomes.
ONCAlert | Upfront Therapy for mRCC
Videos  >  

Emerging Targeted Therapies in Marginal Zone Lymphoma

Nathan H. Fowler, MD
Published Online:5:53 PM, Wed April 10, 2019


Nathan H. Fowler, MD, associate professor in the department of lymphoma/myeloma, at The University of Texas MD Anderson Cancer Center, discusses emerging targeted therapies for the treatment of marginal zone lymphoma.

Frontline combinations of chemotherapy and immunotherapy have shown response rates as high as 80% to 90%, says Fowler. A number of novel targeted drugs have also demonstrated activity in marginal zone lymphoma. Most recently, ibrutinib (Imbruvica) was approved by the FDA, based on data from a phase II trial. The findings showed response rates around 50% and progression-free survival over 12 months.

Other targeted therapies have yet to be approved, but Fowler says that there are several in development now.
Copyright © TargetedOnc 2019 Intellisphere, LLC. All Rights Reserved.